The Effects of Mepolizumab on CRSwNP: Real-Life Evidence.

Autor: Cantone E; Department of Neuroscience, Reproductive Sciences and Dentistry, University of Naples 'Federico II', 80138 Naples, Italy., Cassiano B; UOSD di Otorinolaringoiatria, ASL Napoli 3, Ospedale di Nola, Via delle Repubbliche 7, 80035 Nola, Italy., Pezzella P; Department of Neuroscience, Reproductive Sciences and Dentistry, University of Naples 'Federico II', 80138 Naples, Italy., Russo MB; Department of Engineering, University of Campania 'Luigi Vanvitelli', 81031 Aversa, Italy., Detoraki A; Division of Internal Medicine and Clinical Immunology, Department of Translational Medical Sciences, University of Naples 'Federico II', 80138 Naples, Italy.
Jazyk: angličtina
Zdroj: Journal of personalized medicine [J Pers Med] 2024 Nov 20; Vol. 14 (11). Date of Electronic Publication: 2024 Nov 20.
DOI: 10.3390/jpm14111112
Abstrakt: Background : This study aims to evaluate the efficacy and safety of mepolizumab in the treatment of severe uncontrolled CRSwNP with or without comorbid asthma in a real-life setting over the first six months of therapy. Methods : A total of 45 patients with nasal polyps with or without comorbid asthma were treated with mepolizumab (100 mg q4w) for 6 months. The following outcomes were assessed before therapy (V 0 ), and after 6 months (V 1 ): endoscopic nasal polyp score (NPS), nasal congestion score (NCS), sinonasal outcome test (SNOT-22), visual analog scale (VAS), nasal flow rate (PNIF), olfactory test (SS-I), and asthma control test (ACT). Blood eosinophil count, oral steroid intake, and rescue surgery were also measured. Results : We found a statistically significant improvement in NPS, NCS, SNOT-22, overall VAS, PNIF, SS-I, and ACT. In addition, we observed a decrease in blood eosinophils count. Mepolizumab was well tolerated, and no patients interrupted the treatment during the follow up. Conclusions : Our real-life study confirmed the efficacy and tolerance of mepolizumab prescribed for CRSwNP with or without asthma. The safety profile of mepolizumab was consistent with previous reports.
Databáze: MEDLINE